FY2026 EPS Forecast for Kura Oncology Lifted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for Kura Oncology in a report issued on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($3.19) for the year, up from their previous estimate of ($3.39). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for Kura Oncology’s Q4 2026 earnings at ($0.81) EPS, FY2027 earnings at ($2.16) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at ($1.86) EPS.

KURA has been the subject of several other research reports. JPMorgan Chase & Co. initiated coverage on Kura Oncology in a research report on Thursday, October 1st. They issued an “overweight” rating and a $30.00 price objective for the company. Wedbush increased their target price on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, October 15th. Morgan Stanley set a $24.00 price target on Kura Oncology in a report on Monday, August 24th. Finally, Deutsche Bank set a $24.00 target price on shares of Kura Oncology in a research note on Wednesday, October 14th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $25.88.

Kura Oncology Trading Down 3.9%

KURA stock opened at $7.43 on Friday. The business has a fifty day moving average price of $10.28 and a 200 day moving average price of $9.77. Kura Oncology has a fifty-two week low of $6.75 and a fifty-two week high of $13.90. The stock has a market capitalization of $682.67 million, a price-to-earnings ratio of -2.25 and a beta of 0.56. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.04. The business had revenue of $22.84 million for the quarter, compared to the consensus estimate of $24.94 million. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%.

Institutional Trading of Kura Oncology

Large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Kura Oncology during the 2nd quarter worth $115,286,000. Bank of America Corp DE bought a new stake in shares of Kura Oncology in the second quarter worth about $12,735,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Kura Oncology in the second quarter worth about $10,927,000. Aberdeen Group plc acquired a new stake in shares of Kura Oncology during the third quarter worth about $8,443,000. Finally, Man Group plc acquired a new stake in shares of Kura Oncology during the second quarter worth about $4,749,000.

Insider Activity

In other Kura Oncology news, insider Teresa Bair sold 31,487 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the sale, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mollie Leoni sold 28,802 shares of Kura Oncology stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total transaction of $309,621.50. Following the transaction, the insider directly owned 141,095 shares in the company, valued at approximately $1,516,771.25. This represents a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 153,881 shares of company stock valued at $1,708,183. 7.60% of the stock is currently owned by company insiders.

Kura Oncology News Roundup

Here’s some of the latest news about KURA:

• Positive Sentiment: Kura said it expects to receive $25 million in funding, which could add financial flexibility. Funding announcement
• Neutral Sentiment: HC Wainwright raised its 2026–2029 EPS forecasts, now projecting smaller losses in each year; Brookline also modestly improved its 2026–2028 estimates. These revisions are supportive, but remain projections rather than evidence that Kura has reached profitability.
• Negative Sentiment: Brookline lowered its Q4 2026 EPS estimate, from a loss of $0.89 to $0.97 per share. Its estimate remains more pessimistic than HC Wainwright’s $0.81-per-share loss forecast, underscoring uncertainty around near-term expenses.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.